Therapy Detail

Therapy Name LY294002
Therapy Description

LY294002 is a specific inhibitor of PI3K alpha, beta, and delta, which leads to inhibition of PI3K-Akt/PKB signaling (PMID: 12060641).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
LY294002 PI3K Inhibitor (Pan) 34 LY294002 is a specific inhibitor of PI3K alpha, beta, and delta, which leads to inhibition of PI3K-Akt/PKB signaling (PMID: 12060641).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS G12D Advanced Solid Tumor sensitive LY294002 Preclinical Actionable In a preclinical study, LY294002 reduced phosphorylation of Akt in pancreatic epithelial cells expressing Kras G12D (PMID: 22871572). 22871572
Clinical Trial Phase Therapies Title Recruitment Status